Similar drugs on the market, such as Mounjaro, typically target only two receptors
GCGR/GLP-1R agonist: Beta: -0.26, 95%CI: -0.45 to -0.06, P = 9.28 10 3
This is especially helpful for patients who struggle with frequent snacking or binge eating
Weight management and metabolic health are complex journeys and take longer than usual
Thats without even mentioning the urgent need to find sustainable methods of peptide synthesis
New England Journal of Medicine 2023 03 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial Rosenstock J, Frias J, Jastreboff AM, et al